Table 2 Changes in pulmonary function and body mass index by patient group
From: Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
LFTs annual change/body mass index | Nintedanib group (N = 9) | Non-nintedanib group (N = 6) | Non-treated group (N = 6) | ||||
|---|---|---|---|---|---|---|---|
Pre-treatment | On treatment | P value | Pre-treatment | On treatment | P value | At diagnosis | |
Follow-up duration (days) | 376 ± 370 | 530 ± 382 | – | 1904 ± 2296 | 593 ± 389 | – | 1526 ± 1291 |
Δ FVC (mL) | − 274 ± 188 | − 169 ± 214 | 0.023* | − 193 ± 463 | − 275 ± 607 | NS | − 50 ± 144 |
Absolute Δ FVC (%) | − 13.6 ± 13.4 | − 1.6 ± 6.02 | 0.014* | − 5.4 ± 13.3 | − 6.6 ± 14.9 | NS | + 0.4 ± 6.97 |
Relative Δ FVC (%) | − 20.6 ± 16.9 | − 6.04 ± 14.5 | 0.021* | − 13.2 ± 34 | − 16.6 ± 36.2 | NS | + 0.7 ± 11.8 |
Δ TLC (%) | − 11.1 ± 7. 1 | − 1.9 ± 9.5 | NS | − 2.0 ± 2.4 | − 10.7 ± 11.3 | NS | − 0.3 ± 4.2 |
Δ RV/TLC (%) | + 10.3 ± 18.9 | + 5.5 ± 12.2 | NS | − 0.5 ± 2.8 | + 6.1 ± 28.7 | NS | + 1.4 ± 15.5 |
BMI (kg/m2) | 17.8 ± 2.0 | 16.7 ± 1.8 | 0.031* | 20.8 ± 3.1 | 19.8 ± 3.3 | 0.328 | 20.6 ± 2.8 at diagnosis; 20.0 ± 2.5 at last follow− up; P: 0.232 |